These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 12795263)
1. [Report of the 55th meeting of the American Academy of Neurology. Honolulu, March 29-April 6, 2003]. Becker H; Chochon F; de Toffol B; Defebvre L; Léger JM; Pierrot-Deseilligny C; Sellal F Rev Neurol (Paris); 2003 Apr; 159(4):470-86. PubMed ID: 12795263 [No Abstract] [Full Text] [Related]
2. New developments in the treatment of neurological diseases. Schuster L Drug News Perspect; 2004; 17(6):417-23. PubMed ID: 15334192 [TBL] [Abstract][Full Text] [Related]
3. [American Academy of Neurology, San Diego, 16-23 March 2013]. de Toffol B; Benatru I; Sibon I; Sellal F; Thomas-Anterion C; Léger JM; Pierrot-Deseilligny C Rev Neurol (Paris); 2013 May; 169(5):442-56. PubMed ID: 23602497 [No Abstract] [Full Text] [Related]
4. Key developments in neurology. Silber E Practitioner; 1997 Sep; 241(1578):494-6, 498. PubMed ID: 9926579 [No Abstract] [Full Text] [Related]
5. [American Academy of Neurology, New Orleans, 21-28 April 2012]. Benatru I; de Toffol B; Léger JM; Thomas-Antérion C; Sellal F; Sibon I; Pierrot-Deseilligny C Rev Neurol (Paris); 2012 Jun; 168(6-7):552-65. PubMed ID: 22647808 [No Abstract] [Full Text] [Related]
6. Updates in multiple sclerosis and related disorders: highlights of the 57th Annual Meeting of the American Academy of Neurology, April 9-16, 2005, Miami Beach, FL. Cook SD Rev Neurol Dis; 2005; 2(3):138-43. PubMed ID: 16400314 [No Abstract] [Full Text] [Related]
7. [Borderline forms of multiple sclerosis]. Fontaine B Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):929-34. PubMed ID: 11787357 [TBL] [Abstract][Full Text] [Related]
8. [American Academy of Neurology, Philadelphia, 26 April-3 May, 2014]. Durif F; Sibon I; de Toffol B; Sellal F; Thomas-Anterion C; Léger JM; Pierrot-Deseilligny C Rev Neurol (Paris); 2014; 170(6-7):471-86. PubMed ID: 24880187 [No Abstract] [Full Text] [Related]
12. [Dopamine agonist is effective in Parkinson disease not only against tremor. Depression is also improved]. MMW Fortschr Med; 2002 May; Suppl 2():88. PubMed ID: 12070869 [No Abstract] [Full Text] [Related]
13. [Preliminary clinical studies on the antiparkinson effects of 17-monochloroacetylajmaline]. Errichiello G; Maglione S Minerva Med; 1974 May; 65(41):2357-9. PubMed ID: 4602984 [No Abstract] [Full Text] [Related]
18. Phase II multiclinic study of elantrine in parkinsonism. Blonsky ER; Ericsson AD; McKinney AS; Rix A; Wang RI; Rimm AA Clin Pharmacol Ther; 1974 Jan; 15(1):46-50. PubMed ID: 4587106 [No Abstract] [Full Text] [Related]
19. [American Academy of Neurology, Toronto, April 10-7, 2010]. Bonnaud I; Benatru I; Sellal F; de Toffol B; Léger JM; Pierrot-Deseilligny C Rev Neurol (Paris); 2010 May; 166(5):553-64. PubMed ID: 20466397 [No Abstract] [Full Text] [Related]
20. Practice parameters: initial therapy of Parkinson's disease (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology; 1993 Jul; 43(7):1296-7. PubMed ID: 8327126 [No Abstract] [Full Text] [Related] [Next] [New Search]